As of Feb 17
| -0.46 / -0.65%|
The 21 analysts offering 12-month price forecasts for Gilead Sciences have a median target of 82.00, with a high estimate of 112.00 and a low estimate of 61.00. The median estimate represents a +17.39% increase from the last price of 69.85.
The current consensus among 29 polled investment analysts is to Buy stock in Gilead Sciences. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.